It is possible to manufacture monoclonal antibodies using traditional methods, but the challenges inherent in bispecific antibodies such as low titer, mismatched chains, unwanted fragments and higher aggregation levels require a heightened analytical focus on clonal cell selection. Here, Stuart Jamieson and Alice Harrison at Lonza discuss high-throughput analytical strategies that enable right-first-time selection of the optimal clone to take through to clinical manufacture.

Authors: Stuart Jamieson, Global Technical and CMC Director for Downstream Development; Alice Harrison, Global Technical Director (CMC and Analytics)

By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center